Regeneron queried by US judge over Amgen’s ‘unethical’ PBM rebate bundles
Regeneron Pharmaceuticals’ antitrust claims that Amgen has illegally leveraged secret, “unethical” rebates with pharmacy benefit managers across its broad portfolio of multibillion-dollar drugs came under the microscope of a US federal...To view the full article, register now.
Already a subscriber? Click here to view full article